SAN DIEGO–(BUSINESS WIRE)–Avenzo Therapeutics Announces Oral Presentation of Phase 1 Data for VBC103 (AVZO-103), a Potentially Differentiated Nectin-4/TROP2 BsADC, by VelaVigo

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.